Moolec Science (MLECW) Stock Price, News & Analysis

Company Overview

Moolec Science is a biotechnology company focused on developing gene-edited livestock as living bioreactors to produce therapeutic proteins. The company leverages CRISPR/Cas9 and related gene-editing technologies to introduce human genes into the genome of pigs, enabling the secretion of complex human proteins in sow’s milk. By combining advanced genetic engineering with traditional livestock breeding, Moolec Science aims to address scalability and cost challenges associated with conventional biologics manufacturing.

The company’s pipeline centers on the production of large multimolecular proteins, including coagulation factors and antibody fragments, for rare diseases and life-threatening conditions. Moolec Science’s platform is designed to streamline downstream processing of recombinant proteins directly from milk, reducing reliance on cell culture. The firm has engaged in preclinical studies and is exploring partnerships with pharmaceutical and biotech companies to advance its candidates toward clinical development.

Headquartered in South Korea with subsidiary operations in the United States, Moolec Science combines research and development facilities, gene-editing laboratories, and breeding farms. The company is traded on the Nasdaq Capital Market under the symbol MLECW. Moolec Science’s team brings together expertise in molecular biology, animal sciences, and bioengineering to drive its mission of creating cost-effective, large-scale biopharmaceutical production solutions.

Key Stats

• Today's Range: $0.0175 to $0.0198
• 50-Day Range: $0.01 to $0.02
• 52-Week Range: $0.00 to $0.16
• Volume: 290 shs
• Average Volume: 522,376 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Trading
• Current Symbol: NASDAQ:MLECW
• CIK: 1937737
• Web: moolecscience.com
• Phone: 352-26-49-65-65
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $338.84 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A